EPS for Principia Biopharma Inc. (PRNB) Expected At $-0.31

Analysts expect Principia Biopharma Inc. (NASDAQ:PRNB) to report $-0.31 EPS on February, 5. The stock decreased 2.65% or $0.84 during the last trading session, reaching $30.85. About 22,193 shares traded. Principia Biopharma Inc. (NASDAQ:PRNB) has 0.00% since January 14, 2018 and is . It has by 0.00% the S&P500.

Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. The company has market cap of $736.11 million. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. It currently has negative earnings. The firm has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited.

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.